Expression And Clinical Significance Of IL-22 In Serum Of Patients With Chronic Hepatitis B Liver Failure

Objective: To observe the change of serum IL-22 in patients with chronic hepatitis B liver failure,to explore the relationship between IL-22 and the severity of chronic hepatitis B liver failure and its effect on prognosis.Methods: The patients with chronic hepatitis B liver failure admitted in the Affiliated Hospital of North Sichuan Medical College from February to December 2018 were selected as the experimental group,collecting their serum samples at week 1,week 2 and week 3.During the same period,patients with chronic hepatitis B were selected as the case control group.Healthy subjects were selected as healthy control group.The clinical data and the serum were collected,and the contents of IL-22 in the serum were determined by enzyme-linked immunosorbent assay(ELISA).All of the data was analyzed by SPSS20.0 statistical software.The data of normal distribution was shown as ?x±s.The measurement data meeting the normal distribution and homogeneity of variance was analyzed by the parameter test method.T-test was used for comparison between two groups,and analysis of variance was used for multiple groups.The non-normal distribution or heterogeneity of variance was analyzed by kruskal-wallis H test.The inspection level of alpha is equal to 0.05,P value of less than 0.05 for the difference statistically significant.Results: 1.Compared with the level of IL-22 expression in the serum of the healthy control group,the level of IL-22 in the serum of the chronic hepatitis B group and the chronic hepatitis B liver failure group were significantly increased,with the most significant increase in the chronic hepatitis B liver failure group(p<0.05).2.The baseline level of IL-22 in serum of patients with different prognosis in the chronic hepatitis B liver failure group was compared,and the improved group was slightly higher than the uncured group,but the difference between the two groups was not statistically significant(p>0.05).The changes of IL-22 in the improved group and the uncured group of chronic hepatitis B liver failure were observed dynamically.The level of IL-22 in the improved group showed a downward trend,which was more obvious at week 3,with statistically significant difference(p<0.05).But IL-22 level was always at a high level in the untreated group.3.The changes of IL-22 level and biochemical indexes in the improved group of chronic hepatitis B liver failure were observed dynamically.The expression level of IL-22 in the improved group decreased gradually with the improvement of TBil and PTA,which was more obvious at week 3,with statistically significant difference(p<0.05)4.Compared the baseline level of IL-22 in the group with primary peritonitis and without primary peritonitis in chronic hepatitis B liver failure,the group with primary peritonitis was slightly higher than the group without primary peritonitis,but the difference between the two groups was not statistically significant(p>0.05).The changes of IL-22 in the group with primary peritonitis and the group without primary peritonitis were observed dynamically,and the IL-22 levels in the two groups were compared respectively.The difference of the IL-22 levels between the two groups in the first two weeks was not statistically significant(p>0.05).IL-22 level at week 3 was compared,and the difference was statistically significant(p<0.05).Conclusion: IL-22 was highly expressed in the serum of patients with chronic hepatitis B liver failure,and the expression of IL-22 gradually decreased with the improvement of the disease.There was no correlation between the baseline level of IL-22 and the prognosis of patients with chronic hepatitis B liver failure.Dynamic monitoring of the expression level of IL-22 can better reflect the relationship with the disease.